Article successfully added.

CyFlow™ CD106 PE

CyFlow™ CD106 PE
Alternative Name: INCAM-110, VCAM-1
Antibody: Yes
Antigen: CD106
Application: Flow cytometry
Clonality: monoclonal
Clone: STA
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: PE
Isotype: IgG1
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: BK202948

For Research Use Only

HLDA Workshop HLDA V—WS Code A013 Quantity 100 tests Volume 2.0 mL Immunogen... more
CyFlow™ CD106 PE
HLDA WorkshopHLDA V—WS Code A013
Quantity100 tests
Volume2.0 mL
ImmunogenHuman DS6 T cells
Background InformationCD106 (VCAM-1; vascular cell adhesion molecule-1) is an Ig-like cell surface adhesion molecule binding VLA-4 integrin. VCAM-1 is a potent T cell costimulatory molecule taking part in their positive selection and survival, as well as in adhesion, transendothelial migration and activation of peripheral T cells. VCAM-1 is also involved in endothelial cell-cell contacts. Whereas VCAM-1 normally mediates leukocyte extravasion to sites of tissue inflammation, tumor cells can use overexpressed VCAM-1 to escape T cell immunity. Soluble form of VCAM-1 (sVCAM-1) is an inflammatory marker and can be used also in prognosis of subsequent cariovascular events following acute coronary syndromes.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Leca G, Mansur SE, Bensussan A: Expression of VCAM‑1 (CD106) by a subset of TCR gamma delta‑bearing lymphocyte clones: Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J Immunol. 1995 Feb 1; 154(3):1069‑77. < PMID: 7529789 > | van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I, Mous R, ten Klooster JP, Zwaginga JJ, Hordijk PL: VCAM‑1‑mediated Rac signaling controls endothelial cell‑cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol. 2003 Aug; 285(2):C343‑52. < PMID: 12700137 > | Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA: Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006 Mar; 80(6):2684‑93. < PMID: 16501078 > | Wu TC: The role of vascular cell adhesion molecule‑1 in tumor immune evasion. Cancer Res. 2007 Jul 1; 67(13):6003‑6. < PMID: 17616653 > | Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B: Circulating soluble adhesion molecules ICAM‑1 and VCAM‑1 and their association with clinical outcome, troponin T and C‑reactive protein in patients with acute coronary syndromes. Clin Biochem. 2007 Sep 19; < PMID: 23105687 > | Paessens LC, Singh SK, Fernandes RJ, van Kooyk Y: Vascular cell adhesion molecule‑1 (VCAM‑1 and intercellular adhesion molecule‑1 (ICAM‑1 provide co‑stimulation in positive selection along with survival of selected thymocytes. Mol Immunol. 2008 Jan; 45(1):42‑8. < PMID: 17604837 >